Dr. Bruce A. Chabner, MD
Internal Medicine (Internal Medicine Physician)
100 Blossom Street, Cox 640 Hematology Oncology Associates
Boston, MA 02114
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MA license 80731 -
Medical Oncology Physician
MA license 80731
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $32,305 in total to this clinician.
| Chugai Pharmaceutical Co., LTD. | $32,305 |
|---|
| Travel and Lodging | $18,595 |
|---|---|
| Consulting Fee | $13,680 |
| Food and Beverage | $30.17 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chugai Pharmaceutical Co., LTD. Jan 20, 2025 | Travel and Lodging travel to Yokohama, Japan | $18,208 |
| Chugai Pharmaceutical Co., LTD. Jan 20, 2025 | Consulting Fee | $13,680 |
| Chugai Pharmaceutical Co., LTD. Jan 20, 2025 | Travel and Lodging travel to Yokohama, Japan | $387 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $750 in research payments for these studies, mostly to the institutions running them.
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT03589326
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.